Hormonale Kontrazeption

  • Freimut A. Leidenberger
Chapter

Zusammenfassung

In der frauenärztlichen Praxis ist es eine der wichtigsten ärztlichen Aufgaben, Frauen und Männer über geeignete Methoden der Empfängnisverhütung und Geburtenkontrolle zu informieren. Im Bewußtsein außerordentlich hoher empfängnisverhütender Sicherheit hormonaler Kontrazeptiva, speziell der oralen Formen, wird leicht übersehen, daß es sich bei diesen Formen der Empfängnisverhütung um hochwirksame pharmakologische Substanzen handelt, die wie alle wirksamen Substanzen unerwünschte Arzneiwirkungen aurweisen können. Die Entwicklung möglichst niedrigdosierter Formen der hormonalen Kontrazeption entspricht nicht nur dem ärztlichen Wunsch, schwerwiegende Begleiterscheinungen (z. B. Thrombosen) soweit wie möglich zu vermeiden, sondern auch dem heutigen Trend der Anwenderinnen, subjektive und objektivierbare Beschwerden nicht mehr zu akzeptieren. Daneben hat man gelernt, eine Reihe erwünschter Nebenwirkungen hormonaler Kontrazeptiva therapeutisch oder prophylaktisch zu nutzen (s. Kap. 21.6).

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adams MR, Clarkson TB, Shively CA, Parks JS, Kaplan JR (1990) Oral contraceptives, lipoproteins and atherosclerosis. Am J Obstet Gynecol 163:1388PubMedCrossRefGoogle Scholar
  2. Aktories K, Krog W, Dericks-Tan E, Jiirgensen O, Taubert HD (1976) Die Beeinflussung des Ovarialzyklus durch verschiedene Typen hormonaler Kontrazeptiva. Geburtshilfe Frau-enheilkd 36:318Google Scholar
  3. Andersson K, Odlind V, Rybo G (1994) Levonorgestrel-relea-sing and copper-releasing (Nova T) IUDs during five years of use: A randomized comparative trial. Contraception 49: 56PubMedCrossRefGoogle Scholar
  4. Anon A (1992) Does infection occur with modern intrauterine devices? Lancet 339: 783CrossRefGoogle Scholar
  5. Aref I, Hefnawi F, Kandil O (1973 a) Changes in human ovaries after longterm administration of microdose progestogens. Contraception 7: 503CrossRefGoogle Scholar
  6. Aref I, Hefnawi F, Kandil O, Abdel Aziz MT (1973 b) Effect of minipills on physiologic responses of human cervical mucus, endometrium, and ovary. Fertil Steril 24: 578PubMedGoogle Scholar
  7. Asherson RA, Harris NE, Gharavi AE, Hughes GR (1986) Systemic lupus erythematosus, antiphospholipid antibodies, chorea, and oral contraceptives. Arthritis Rheum 29:1535PubMedCrossRefGoogle Scholar
  8. Astedt B (1971) Low fibrinolytic activity of veins during treatment with ethinylestradiol. Acta Obstet Gynecol Scand 50:279PubMedCrossRefGoogle Scholar
  9. Aufdemorte TB, Sheridan PJ (1981) Nuclear uptake of sex steroids in gingiva of the baboon. J Periodontol 52: 430PubMedCrossRefGoogle Scholar
  10. Bäckström T (1983) Premenstrual tension syndrome. In: Bar-din CW, Milgröm E, Mauvais-Jarvis P (eds) Progesteron and progestins. Raven, New York, p 203Google Scholar
  11. Bain C, Hennekens CH, Speizer FE, Rosner B, Willett W, Belanger C (1982) Oral contraceptive use and malignant melanoma. JNCI 68: 537PubMedGoogle Scholar
  12. Barbosa I, Bakos O, Olsson SE, Ohlind V, Johansson EDB (1990) Ovarian function during use of a Levonorgestrel-releasing IUD. Contraception 42: 51PubMedCrossRefGoogle Scholar
  13. Bässler R, Kind M (1989) Pathologie, Systematik und Klassifizierung gutartiger Brusterkrankungen. Gynäkologe 22: 216PubMedGoogle Scholar
  14. Basu J, Vermund SH, Mikhail M, Palan PR, Romney SL (1989) Plasma reduced and total ascorbic acid in healthy women: effects of smoking and oral contraception. Contraception 39:85PubMedCrossRefGoogle Scholar
  15. Beck P (1977) Effect of progestins on glucose and lipid metabolism. Ann NY Acad Sci 286: 434PubMedCrossRefGoogle Scholar
  16. Benson MD, Rebar WR (1986) Relationship of migraine headache and stroke to oral contraceptive use. J Reprod Med 31: 1082PubMedGoogle Scholar
  17. Beral V, Ramcharan S, Faris R (1977) Malignant melanoma and oral contraceptive use among women in California. Br J Cancer 36: 804PubMedCrossRefGoogle Scholar
  18. Bettendorf G (1974) Wirkung hormonaler Ovulationshemmer auf die Haut. Kosmetologie 4:150Google Scholar
  19. Bork K, Bräuninger W, Czarnetzki BM, Addicks B, Paul E, Glitsch M, Noack C (1985) Schwangerschaft nach malignem Melanom. Dtsch Med Wochenschr 110:1323PubMedCrossRefGoogle Scholar
  20. Böttiger LE, Boman G, Eklund G, Westerholm B (1980) Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1:1097PubMedCrossRefGoogle Scholar
  21. Boston Collaborative Drug Surveillance Programme (1973) Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumors. Lancet 1:1399Google Scholar
  22. Breckwoldt M (1990) Stellungnahme der Arbeitsgemeinschaft für gynäkologische Endokrinologie. Niedrig dosierte Kontrazeptiva und Thromoboembolierisiko. Frauenarzt 31: 329Google Scholar
  23. Breckwoldt M, Zahradnik HP (1987) Pathophysiologie der Dysmenorrhoe. In: Mall-Haefeli M (Hrsg) Wirkung kontrazeptiver Steroide. Mit Unterstützung durch Organon, Oberschleißheim, S 7Google Scholar
  24. Brooks PG (1984) Pill formulations and their effect on lipid and carbohydrate metabolism. J Reprod Med 29 (Suppl): 539PubMedGoogle Scholar
  25. Buehring GC (1988) Oral contraceptives and breast cancer: what has 20 years of research shown? Biomed Pharmacother 42: 525PubMedGoogle Scholar
  26. Casagrande JT, Pike MC, Ross RK, Louie EW, Roy S, Henderson BE (1979) „Incessant ovulation” and ovarian cancer. Lancet July 28:170CrossRefGoogle Scholar
  27. The Centers for Disease Control Cancer and Steroid Hormone Study (1983a) Longterm oral contraceptive use and the risk of breast cancer. JAMA 249:1591CrossRefGoogle Scholar
  28. The Centers for Disease Control Cancer and Steroid Hormone Study (1983b) Oral contraceptive use and the risk of ovarian cancer. JAMA 249:1596CrossRefGoogle Scholar
  29. The Centers for Disease Control Cancer and Steroid Hormone Study (1983c) Oral contraceptive use and the risk of endometrial cancer. JAMA 249:1600CrossRefGoogle Scholar
  30. The Centers for Disease Control Cancer and Steroid Hormone Study and the National Institute of Child Health and Human Development (1986) Oral contraceptive use and the risk of breast cancer. N Engl J Med 315: 405CrossRefGoogle Scholar
  31. Clarke EA, Hatcher J, McKeown-Eyssen GE, Lickrish GM (1985) Cervical dysplasia: association with sexual behavior, smoking and oral contraceptive use? Am J Obstet Gynecol 151:612PubMedGoogle Scholar
  32. Conell EB, Kelman CD (1968) Ophthalmologic findings with oral contraceptives. Obstet Gynecol 31: 456Google Scholar
  33. Cramer DW, Goldman MB, Schiff I et al. (1987) The relationship of tubal infertility to barrier method and oral contraceptives use. JAMA 257: 2446PubMedCrossRefGoogle Scholar
  34. Croft P, Hannaford PC (1989) Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners oral contraception study. Br Med J 298:165CrossRefGoogle Scholar
  35. Cuckle HS, Wald NJ (1982) Evidence against oral contraceptives as a cause of neural tube defects. Br J Obstet Gynaecol 89:547PubMedCrossRefGoogle Scholar
  36. De Pirro R, Forte F, Bertoli A, Greco AV, Lauro R (1981) Changes in insulin receptors during oral contraception. J Clin Endocrinol Metab 52: 29PubMedCrossRefGoogle Scholar
  37. De Stefano F, Peterson HB, Ory HW, Layde PM (1982) Oral contraceptives and postoperative venous thrombosis. Am J Obstet Gynecol 143: 227Google Scholar
  38. Dericks-Tan JSE, Taubert HD (1976) Elevation of serum prolactin during application of oral contraceptives. Contraception 14:1PubMedCrossRefGoogle Scholar
  39. Dericks-Tan JSE, Schneider K, Taubert HD (1980) The mechanism of action of a new low-dosed combined oral contraceptive. Arch Gynäkol 229:107Google Scholar
  40. Diamond MP, Greene JW, Thrompson JM, Hooydonk van JE, Wentz AC (1985) Interaction of anticonvulsants and oral contraceptives in epileptic adolescents. Contraception 31: 623PubMedCrossRefGoogle Scholar
  41. Diddle AW, Gardner WH, Williamson PJ (1969) Oral contraceptive medications and headache. Am J Obstet Gynecol 105:507PubMedGoogle Scholar
  42. Döring GK, Kauka E, Netzer A (1976) Schwangerschaftsverlauf und Zustand der Kinder nach Anwendung von Ovulationshemmern. Geburtshilfe Frauenheilkd 36:57PubMedGoogle Scholar
  43. Dreyer NA, Pizzo SV (1980) Blood coagulation and idiopathic thromboembolism among fertile women. Contraception 22: 123PubMedCrossRefGoogle Scholar
  44. Durber SM, Lawson J, Daly JR (1976) The effect of oral contraceptives on plasma Cortisol and Cortisol binding capacity throughout the menstrual cycle in normal women. Br J Obstet Gynaecol 83: 814PubMedCrossRefGoogle Scholar
  45. Ebeling K, Nischan P, Schindler C (1987) Use of oral contraceptives and risk of invasive cervical cancer in previously screened women. Int J Cancer 39: 427PubMedCrossRefGoogle Scholar
  46. Eddy G, Schlaerth JB, Nalick RH, Gaddis O Jr, Nakamura RM, Morrow CP (1983) Postmolar trophoblastic disease in women using hormonal contraception with and without estrogen. Obstet Gynecol 62: 736PubMedGoogle Scholar
  47. Eichhorn KH, Carol W, Heine A, Klinger G (1975) Beitrag zum Nachweis der Unbedenklichkeit hormonaler Kontrazeptiva auf nachfolgende Schwangerschaften. Zentralbl Gynäkol 97: 481Google Scholar
  48. El-Mahgoub S, Karim M, Ammar R (1972) Longterm effects of injectable progestogens on the morphology of the human oviducts. J Reprod Med 8: 288PubMedGoogle Scholar
  49. Elstein M, Morris SE, Groom GV, Jenner DA, Scarisbrick JJ, Cameron EHD (1976) Studies on low dose oral contraceptives: cervical mucus and plasma hormone changes in relation to circulating d-norgestrel and 17α-ethinyl estradiol concentrations. Fertil Steril 27: 892PubMedGoogle Scholar
  50. Engel HJ, Engel E, Behnke K, Lichtlen P (1987) Angiographische Befunde nach Herzinfarkt junger Frauen: die Rolle oraler Kontrazeptiva. Herz 12: 290PubMedGoogle Scholar
  51. Eschenbach DA, Harnisch JP, Holmes KK (1977) Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors. Am J Obstet Gynecol 128: 838PubMedGoogle Scholar
  52. Fasal E, Paffenbarger RS (1975) Oral contraceptives as related to cancer and benign lesions of the breast. J Natl Cancer Inst 55: 767PubMedGoogle Scholar
  53. Fasoli M, Parazzini F, Ceccetti G, La Vecchia C (1989) Postcoital contraception: an overview of published studies. Contraception 39: 459PubMedCrossRefGoogle Scholar
  54. Fisch IR, Frank J (1977) Oral contraceptives and blood pressure. JAMA 237: 2499PubMedCrossRefGoogle Scholar
  55. Fisch IR, Freedman SH, Myatt AV (1972) Oral contraceptives, pregnancy, and blood pressure. JAMA 222:1507PubMedCrossRefGoogle Scholar
  56. Fischer RI, Neifeld JP, Lippman ME (1976) Oestrogen receptors in human malignant melanoma. Lancet August 14:337CrossRefGoogle Scholar
  57. Fournier von D, Junkermann H, Krapfl E, Anton HW, Stolz W, Heep J (1989) überblick über Therapieformen gutartiger Brusterkrankungen. Gynäkologe 22: 246Google Scholar
  58. Franceschi S, La Vecchia C, Parazzini F et al. (1984) Oral contraceptives and benign breast disease: a case-control study. Am J Obstet Gynecol 149: 602PubMedGoogle Scholar
  59. Fraser IS, Jansen RPS (1983) Why do inadvertent pregnancies occur in oral contraceptive users. Contraception 27: 531PubMedCrossRefGoogle Scholar
  60. Freundl G, Brossmann H (1985) Ovulationshemmer und Tumoren. Dtsch Med Wochenschr 110:1346PubMedCrossRefGoogle Scholar
  61. Frick V (1978) Störfaktor Sicherheit. Sexualmedizin 3: 221Google Scholar
  62. Gabius S, Blossey TH, Teichmann AT, Nagel GA (1988) Sind östrogene beim Mammakarzinom kontraindiziert? DMW 45:1774Google Scholar
  63. Garmenia F, Kesserü E, Llerena LA (1973) Serum LH concentrations in women under contraceptive treatment with estrogen-free progestagens. Horm Metab Res 5:134CrossRefGoogle Scholar
  64. Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier J (1984) Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel. Contraception 29:305PubMedCrossRefGoogle Scholar
  65. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ (1991) Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133:32PubMedGoogle Scholar
  66. Goebel R, Junkermann H, Fournier von D (1989) Danazolthe-rapie bei gutartigen Brusterkrankungen. Gynäkologe 22:262PubMedGoogle Scholar
  67. Goldstein JL, Brown MS (1977) The low-density lipoprotein pathway and its relation to atherosclerosis. Ann Rev Bio-chem 46: 897CrossRefGoogle Scholar
  68. Goldzieher JW, Kleber JW, Moses LE, Rathmacher RP (1970) A cross-sectional study of plasma FSH and LH levels in women using sequential, combination or injectable steroid contraceptives over long periods of time. Contraception 2: 225CrossRefGoogle Scholar
  69. Goldzieher JW, Moses LE, Averkin E, Scheel C, Taber BZ (1971 a) A placebo controlled double blind crossover investigation of the side effects attributed to oral contraceptives. Fertil Steril 22: 609PubMedGoogle Scholar
  70. Goldzieher JW, Moses LE, Averkin E, Scheel C, Taber BZ (1971b) Nervousness and depression attributed to oral contraceptives: A double-blind, placebo-controlled study. Am J Obstet Gynecol 111:1013PubMedGoogle Scholar
  71. Göttlicher S, Madjaric J (1981) Neue Ergebnisse zur Frage eines Zusammenhangs zwischen oraler Kontrazeption und vaginalem Sproßpilzbefall. Geburtshilfe Frauenheilkd 41: 630PubMedCrossRefGoogle Scholar
  72. Gray RH (1985) Reduced risk of pelvic inflammatory disease with injectable contraceptives. Lancet 1:1046PubMedCrossRefGoogle Scholar
  73. Guillebaud J (1983) The 150/30 formulation. Experience in the United Kingdom. J Reprod Med 28 (Suppl): 66PubMedGoogle Scholar
  74. Hammerstein J (1977) Komplikationen und Spätfolgen der Kontrazeption einschließlich der Sterilisation. Arch Gynäkol 224:1PubMedCrossRefGoogle Scholar
  75. Hammerstein J (1978) Mißbildungen nach Behandlung schwangerer Frauen mit weiblichen Sexualhormonen. Stellungnahme der „Ständigen Kommission Steroidtoxikologie” der Deutschen Gesellschaft für Endokrinologie, Ulm. Endo-krinologie-Information, Demeter, Gräfelfing 3:102Google Scholar
  76. Hammerstein J (1984) Grundsätzliche Betrachtung zur Wahl der Methode bei Mann und Frau. Gynäkologe 17:156PubMedGoogle Scholar
  77. Hammerstein J (1990) Risk/benefit of oral contraceptives. (Vortrag auf dem III. Internationalen Symposium zur Kontrazeption, Heidelberg, 19.–23.6.1990)Google Scholar
  78. Hanson M, Hatcher RA, Mishell DR, Notelovitz M, Spellacy WN (1985) Update on oral contraceptives. J Reprod Med 30 (Suppl): 691PubMedGoogle Scholar
  79. Harlap S, Shiono PH, Ramcharan S (1985) Congenital abnormalities in the offspring of women who used oral and other contraceptives around the time of conception. Int J Fertil 30:39PubMedGoogle Scholar
  80. Helmrich SP, Rosenberg L, Kaufman DW, Strom B, Shapiro S (1987) Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 69: 91PubMedGoogle Scholar
  81. Hirvonen E, Stenman UH, Mälkönen M, Rasi V, Vartiainen E, Ylöstalo P (1988) New natural oestradiol/cyproterone acetate oral contraceptive for pre-menopausal women. Maturi-tas 10: 201CrossRefGoogle Scholar
  82. Hislop TG, Threlfall WJ (1984) Oral contraceptives and benign breast disease. Am J Epidemiol 120: 273PubMedGoogle Scholar
  83. Hocevar V, Rausch-Strooman JG (1968) Zur Frage der Behandlung der akuten intermittierenden Porphyrie mit Ovulationshemmern. Klin Wochenschr 46:1114PubMedCrossRefGoogle Scholar
  84. Hofmann AD (1984a) Contraception in adolescence: a review. 1. Psychosocial aspects. Bull WHO 62:151PubMedGoogle Scholar
  85. Hofmann AD (1984b) Contraception in adolescene: a review. 2. Biomedical aspects. Bull WHO 62:331PubMedGoogle Scholar
  86. Hollwich F, Verbeck B (1969) Nebenwirkungen der Ovulationshemmer am Auge. Dtsch Med Wochenschr 94:1761PubMedGoogle Scholar
  87. Hopmann R (1968) Akute intermittierende ovulozyklische Porphyrie und ihre Behandlung. Dtsch Med Wochenschr 93: 76PubMedCrossRefGoogle Scholar
  88. Huber FB (1967) Schwangerschaft und orale hormonelle Contraceptiva bei Porphyriekranken. Schweiz Med Wochenschr 97:1498PubMedGoogle Scholar
  89. Huggins GR, Zucker PK (1987) Oral contraceptives and neoplasia: 1987 update. Fertil Steril 47:733PubMedGoogle Scholar
  90. Hugo von R (1986) Die Bedeutung der Sexualsteroide für die Entstehung venöser Gefäßerkrankungen der Frau. Hormonale Kontrazeption und Kreislauf. 6. Internationales Gespräch Münster/München. Informed, Gräfelfing, S 59Google Scholar
  91. Ippen H, Tesche S (1972) Das „Chloasma” außerhalb der Gravidität. Hautarzt 23: 21PubMedGoogle Scholar
  92. Jain AK (1976) Cigarette smoking, use of oral contraceptives and myocardial infarction. Am J Obstet Gynecol 126:301PubMedGoogle Scholar
  93. Janerich DT, Glebatis DM, Dugan JM (1977) Benign breast disease and oral contraceptive use. JAMA 237: 2199PubMedCrossRefGoogle Scholar
  94. Jick H, Porter J, Rothman KJ (1978a) Oral contraceptives and nonfatal stroke in healthy young women. Ann Intern Med 88: 58CrossRefGoogle Scholar
  95. Jick H, Dinan B, Kenneth J, Rothman KJ (1978b) Oral contraceptives and nonfatal myocardial infarction. JAMA 239: 1403PubMedCrossRefGoogle Scholar
  96. Jick SS, Walker AM, Stergachis A, Jick H (1989) Oral contraceptives and breast cancer. Br J Cancer 59: 618PubMedCrossRefGoogle Scholar
  97. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346:1589PubMedCrossRefGoogle Scholar
  98. Judd SJ, Kerin J (1986) Contraception and diabetes mellitus. Clin Reprod Fertil 4: 297PubMedGoogle Scholar
  99. Kaiser R, Kloppenburg W, Ehmke H, Schwenk H (1987) Menstruationszyklus nach hormonaler Wachstumshemmung bei Mädchen. Geburtshilfe Frauenheilkd 47: 410PubMedCrossRefGoogle Scholar
  100. Kalkhoff RK (1972) Effects of oral contraceptive agents and sex steroids on carbohydrate metabolism. Ann Rev Med 23: 429PubMedCrossRefGoogle Scholar
  101. Kalkhoff RK (1982) Metabolic effects of progesterone. Am J Obstet Gynecol 142:735PubMedGoogle Scholar
  102. Kasan PN, Andrews J (1980) Oral contraception and congenital abnormalities. Br J Obstet Gynaecol 87:545PubMedCrossRefGoogle Scholar
  103. Kaufman DW, Shapiro S, Slone D et al. (1980) Decreased risk of endometrial cancer among oral contraceptive users. N Engl J Med 303:1045PubMedCrossRefGoogle Scholar
  104. Kay CR, Hannaford PC (1988) Breast cancer and the pill a- a further report from the Royal College of General Practitioners’ oral contraception study. Br J Cancer 58: 675PubMedCrossRefGoogle Scholar
  105. Keifer WS, Scott JC (1977) Liver neoplasms and the oral contraceptives. Am J Obstet Gynecol 128: 448PubMedGoogle Scholar
  106. Keller PJ (1986) Chemie und Pharmakologie der synthetischen Gestagene. Endokrinologisches Arbeitstreffen „Kontrazeptive Gestagene”. Thieme, Stuttgart, S 3Google Scholar
  107. Killick S, Eyong E, Elstein M (1987) Ovarian follicular development in oral contraceptive cycles. Fertil Steril 48: 409PubMedGoogle Scholar
  108. Klinger G, Eick S, Klinger G, Pfister W, Oettel M (1996) Der Ein-fluß hormonaler Kontrazeptiva auf die mikrobielle Flora des gingivalen Sulkus. (Eingereicht bei Contraception)Google Scholar
  109. Knopp RH (1986) Arteriosclerosis risk. The roles of oral contraceptives and postmenopausal estrogens. J Reprod Med 31 (Suppl): 913PubMedGoogle Scholar
  110. Kornman KS, Loesche WJ (1979) The subgingival microbial flora during pregnancy. J Periodontal Res 15:111CrossRefGoogle Scholar
  111. Krahulec I, Urbanova O, Simko S (1977) Prispevok K Studiu zmien hlasu pri homronalnej antikoncepcii. (A contribution to the study of voice changes in hormonal contraception.) Ceskoslovenska Otolaryngologic 26: 234Google Scholar
  112. Kreek MJ, Sleisenger MH, Jeffries GH (1967) Recurrent cholestatic jaundice of pregnancy with demonstrated estrogen sensitivity. Am J Med 43:795PubMedCrossRefGoogle Scholar
  113. Kristen K (1976) Veränderungen der Mundschleimhaut während der Schwangerschaft und kontrazeptiver Hormonbehandlung. Fortschr Med 94: 52PubMedGoogle Scholar
  114. Kuhl H (1987) Progestagene zur Empfängnisverhütung. WMW 18: 433Google Scholar
  115. La Vecchia C, Franceschi S, Decarli A (1984) Oral contraceptive use and the risk of epithelial ovarian cancer. Br J Cancer 50:31PubMedCrossRefGoogle Scholar
  116. Lähteenmäki P (1992) Health benefits of a levonorgestrel releasing IUD. 7th Europ Congr Gynaecol Obstet, HelsinkiGoogle Scholar
  117. Landthaler M, Braun-Falco O (1985) Maligne Melanome in der Schwangerschaft. Dtsch Med Wochenschr 35:1319CrossRefGoogle Scholar
  118. Lauritzen C (1987) Hormonale Kontrazeption. Adam Pharma-verlag, EssenGoogle Scholar
  119. Leys D, Destée A, Petit H, Warot P (1987) Chorea associated with oral contraception. J Neurol 235: 46PubMedCrossRefGoogle Scholar
  120. Linn S, Schoenbaum SC, Monson RR, Rosner B, Stubblefield PG, Ryan KJ (1983) Lack of association between contraceptive usage and congenital malformations in offspring. Am J Obstet Gynecol 147: 923PubMedGoogle Scholar
  121. Loudon NB, Foxwell M, Potts DM, Guild AL, Short RV (1977) Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regiment. Br Med J II: 487CrossRefGoogle Scholar
  122. Louv WC, Austin H, Perlman J, Alexander WJ (1989) Oral contraceptive use and the risk of chlamydial and gonococcal infections. Am J Obstet Gynecol 160:396PubMedCrossRefGoogle Scholar
  123. Lundström V, Geijerstam G (1983) Treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand 113 (Suppl): 83CrossRefGoogle Scholar
  124. Luukkainen T, Alionen H, Haukkamaa M, Lähteenmäki P, Nils-son CG, Toivonen J (1986) Five years experience with Levo-norgestrel-releasing IUDs. Contraception 33:139PubMedCrossRefGoogle Scholar
  125. Magos AL, Brincat M, Studd JWW et al. (1985) Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 65: 496PubMedGoogle Scholar
  126. Mall-Haefeli M, Werner-Zodrow I, Huber PR, Edelmann A (1988) Oral contraception and ovarian function. In: Runne-baum B, Rabe T, Kiesel L (eds) Female contraception, update and trends. Springer, Berlin Heidelberg New YorkGoogle Scholar
  127. Mammen EF (1982) Oral contraceptives and blood coagulation. A critical review. Am J Obstet Gynecol 142: 781PubMedGoogle Scholar
  128. Mammen EF (1986) Der Einfluß oraler Kontrazeptiva auf das hämostatische System. Hormonale Kontrazeption und Herzkreislauf. 6. Internationales Gespräch Münster/München 1986. Informed, Gräfelfing, S 47Google Scholar
  129. Mammen EF (1987) Wirkung oraler Kontrazeptiva auf die Blutgerinnung. In: Beller FK, Giesing M, Graeff H (Hrsg) Hormonale Kontrazeption und Herzkreislauf. Informed, Gräfe-ling, S 85Google Scholar
  130. Mammen EF (1990) Epidemiologische Studien zur Hämostase bei Benutzern oraler Kontrazeptiva. In: Keil TU (Hrsg) Kontrazeption — Nutzen — Probleme — Risiken — Perspektiven (III. Internationales Symposium über Kontrazeption, Heidelberg, 19.–23.6.1990). Urban & Vogel, München, S 48Google Scholar
  131. Mann RD (1990) Oral contraceptives and breast cancer. Parthenon, Casterton HallGoogle Scholar
  132. Mason B, Oakley N, Wynn V (1973) Studies of carbohydrate and lipid metabolism in women developing hypertension on oral contraceptives. Br Med J III: 317CrossRefGoogle Scholar
  133. Mathur AK, Gatter RA (1988) Chorea as the initial presentation of oral contraceptive induced systemic lupus erythematosus. J Rheumatol 15: 6Google Scholar
  134. McPherson K, Vessey MP, Neil A, Doll R, Jones L, Roberts M (1987) Early oral contraceptive use and breast cancer: results of another case-control study. Br J Cancer 56: 653PubMedCrossRefGoogle Scholar
  135. Meirik O, Farley TMM, Lund E et al. (1989) Breast cancer and oral contraceptives: patterns of risk among parous and nulli-parous women — further analysis of the Swedish-Norwegian material. Contraception 39:471PubMedCrossRefGoogle Scholar
  136. Meng M (1972) Erfahrungen mit der Minipille. Schweiz Rundsch Med (Praxis) 61: 519Google Scholar
  137. Miller DR, Rosenberg L, Kaufman DW, Stolley P, Warshauer ME, Shapiro S (1989) Breast cancer before age 45 and oral contraceptive use: new findings. Am J Epidemiol 129: 269PubMedGoogle Scholar
  138. Milsom I, Andersch B (1984) Effect of various oral contraceptive combinations on dysmenorrhea. Gynecol Obstet Invest 17: 284PubMedCrossRefGoogle Scholar
  139. Mishell DR (1982) Noncontraceptive health benefits of oral steroidal contraceptives. Am J Obstet Gynecol 142: 809PubMedGoogle Scholar
  140. Molina R, Thomas DB, Dabancens A, Lopez J, Ray RM, Martinez L, Salas O (1988) Oral contraceptives and cervical carcinoma in situ in Chile. Cancer Res 48:1011PubMedGoogle Scholar
  141. Molina R, Martinez C, Salas O et al. (1989) Combined oral contraceptives and liver cancer. Int J Cancer 43: 254CrossRefGoogle Scholar
  142. Morrow P, Nakamura R, Schlaerth J, Gaddis O, Eddy G (1985) The influence of oral contraceptives on the postmolar human chorionic gonadotropin regression curve. Am J Obstet Gynecol 151: 906PubMedGoogle Scholar
  143. Newton J (1988) Contraception for the women aged 35 year and over. Maturitas 1: 89PubMedCrossRefGoogle Scholar
  144. Nocke W (1978) Sind weibliche Sexualsteroide teratogen? Rückblick — Zwischenbilanz — Konsequenzen. Gynäkologe 11:119Google Scholar
  145. Olsson H, Lindahl B, Ranstam J, Borg A, Fernö M, Norgren A (1987) Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age. Anticancer Res 7: 853PubMedGoogle Scholar
  146. Olsson H, Möller TR, Ranstam J, Borg A, Fernö M (1988) Early oral contraceptive use as a prognostic factor in breast cancer. Anticancer Res 8: 29PubMedGoogle Scholar
  147. Olsson H, Möller TR, Ranstam J (1989) Early oral contraceptive use and breast cancer among premenopausal women. Final report from a study in southern Sweden. J Natl Cancer Inst 81:1000PubMedCrossRefGoogle Scholar
  148. Pahn J, Göretzlehner G (1978) Stimmstörungen durch hormonale Kontrazeptiva. Zentralbl Gynäkol 100: 341PubMedGoogle Scholar
  149. Pahn J, Göretzlehner G (1979) Hormonale Kontrazeptiva und Stimmstörungen. HNO-Praxis 4: 220Google Scholar
  150. Pain JA, Gimson AES, Williams R, Howard ER (1991) Focal nodular hyperplasia of the liver: results of treatment and options of management. GUT 32:524PubMedCrossRefGoogle Scholar
  151. Pascher W, Bauer H (1984) Entwicklungsstörungen der Stimme. In: Pascher W, Bauer H (Hrsg) Differentialdiagnose von Sprach-, Stimm- und Hörstörungen. Thieme, StuttgartGoogle Scholar
  152. Pearl R (1932) Contraception and fertility in 2000 women. Hum Biol 4: 363Google Scholar
  153. Perlroth MG, Marver HS, Tschudy DP (1965) Oral contraceptive agents and the management of acute intermittent porphyria. JAMA 194:1037PubMedCrossRefGoogle Scholar
  154. Petersen P (1978) Seelische Veränderungen bei hormonaler Kontrazeption der Frau. Dtsch ärztebl 18:1075Google Scholar
  155. Petitti DB (1986) Epidemiologic assessment of the risks of oral contraception. J Reprod Med 31: 887PubMedGoogle Scholar
  156. Petitti DB, Wingerd J (1978) Use of oral contraceptives, cigarette smoking, and risk of subarachnoid haemorrhage. Lancet II: 234CrossRefGoogle Scholar
  157. Petitti DB, Wingerd J, Pellegrin F, Ramcharan S (1978) Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease. Am J Epidemiol 108: 480PubMedGoogle Scholar
  158. Petitti DB, Wingerd J, Pellegrin F, Ramcharan S (1979) Risk of vascular disease in women. JAMA 242:1150PubMedCrossRefGoogle Scholar
  159. Pike MC, Henderson BE, Casagrande JT, Rosario I, Gray GE (1981) Oral contraceptive use and early abortion as risk factors for breast in young women. Br J Cancer 43: 72PubMedCrossRefGoogle Scholar
  160. Pituitary Adenoma Study Group (1983) Pituitary adenomas and oral contraceptives: a multicenter case control study. Fertil Steril 39: 753Google Scholar
  161. Podoshin L, Gertner R, Fradis M, Feiglin H, Eibschitz I, Sharf M, Reiter A (1978) Oral contraceptives pills and clinical otosclerosis. Int J Gynaecol Obstet 15: 554PubMedGoogle Scholar
  162. Poettgen H (1989) Wenn ich Jugendlichen die Pille verordnen soll. Sexualmedizin 6:310Google Scholar
  163. Porter JB, Hunter JR, Jick H, Stergachis A (1985) Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 66:1PubMedGoogle Scholar
  164. Porter JB, Jick H, Walker AM (1987) Mortality among oral contraceptive users. Obstet Gynecol 70: 29PubMedGoogle Scholar
  165. Poser S, Raun NE, Wikström J, Poser W (1979) Pregnancy, oral contraceptives and multiple sclerosis. Acta Neurol Scand 59: 108PubMedCrossRefGoogle Scholar
  166. Rabe T, Runnebaum B (1982) Kontrazeption. Springer, Berlin Heidelberg New York TokyoCrossRefGoogle Scholar
  167. Rabe T, Grunwald K, Runnebaum B (1988) Pille und Kohlenhydratstoffwechsel. Fertilität 4: 97Google Scholar
  168. Rahn KH (1984) äußerungen von Schäden an der Haut. In: Rahn KH (Hrsg) Erkrankungen durch Arzneimittel. Thieme, StuttgartGoogle Scholar
  169. Ramcharan S (1974) The Walnut Creek contraceptive drug study: a prospective study of the side effects of oral contraceptives, vol I. Findings in oral contraceptive users and nonusers at entry into the study. US Government Printing Office, Washington DCGoogle Scholar
  170. Ramcharan S (1976) The Walnut Creek contraceptive drug study: a prospective study of the side effects of oral contraceptives, vol II. Additional findings of oral contraceptive users and nonusers. US Government Printing Office, Washington DCGoogle Scholar
  171. Ramcharan S, Pellegrin FA, Ray R, Hsu JP (1980) The Walnut Creek contraceptive drug study, vol III. Center for Population Research, Bethesda MDGoogle Scholar
  172. Realini JP, Goldzieher JW (1985) Oral contraceptives and cardiovascular disease: a critique of the epidemiologic studies. Am J Obstet Gynecol 152: 729PubMedGoogle Scholar
  173. Rechenberger I (1989) Psychosomatische Aspekte des prämenstruellen Syndroms. Gynäkologe 22:332PubMedGoogle Scholar
  174. Reisert PM (1983) Hormonell verursachte Stimmstörungen. Therapiewoche 33:3661Google Scholar
  175. Resnik S (1967) Melasma induced by oral contraceptive drugs. JAMA 199: 601PubMedCrossRefGoogle Scholar
  176. Rice-Wray E, Beristain II, Cervantes A (1972) Clinical study of a continuous daily microdose progestogen contraceptive -d-norgestrel. Contraception 5: 279PubMedCrossRefGoogle Scholar
  177. Rocheis R, Nover A (1980) Nebenwirkungen oraler Kontrazeptiva am Auge. Geburtshilfe Frauenheilkd 40: 713CrossRefGoogle Scholar
  178. Rock CL, Hall WD (1978) Effect of oral contraceptives on salt taste thresholds. Clin Res 26:368AGoogle Scholar
  179. Rooks JB, Ory HW, Ishak K, Strauss LT, Greenspan JR, Paganini-Hill A, Tyler CW (1979) Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 242: 644PubMedCrossRefGoogle Scholar
  180. Rosenberg L, Shapiro S, Stone D, Kaufman DW et al. (1982) Epithelial ovarian cancer and combination oral contraceptives. JAMA 247:3210PubMedCrossRefGoogle Scholar
  181. Royal College of General Practitioners (1974) Oral contraceptives and health; an interim report from the oral contraception study of the Royal College of General Practitioners. Pitman, New YorkGoogle Scholar
  182. Royal College of General Practitioners’ Oral Contraceptive Study (1976a) The outcome of pregnancy in former contraceptive users. Br J Obstet Gynaecol 83: 608CrossRefGoogle Scholar
  183. Royal College of General Practitioners’ Oral Contraceptive Study (1976b) Pregnancy after oral contraception. Lancet II: 555Google Scholar
  184. Royal College of General Practitioners’ Oral Contraceptive Study (1977a) Effect of hypertension and benign breast disease of progestagen component in combined oral contraceptives. Lancet I: 624Google Scholar
  185. Royal College of General Practitioners’ Oral Contraceptive Study (1977b) Mortality among oral contraceptive users. Lancet II: 727Google Scholar
  186. Royal College of General Practitioners’ Oral Contraceptive Study (1978a) Oral contraceptives, venous thrombosis, and varicose veins. J R Coll Gen Pract 28:393Google Scholar
  187. Royal College of General Practitioners’ Oral Contraceptive Study (1978b) Reduction in incidence of rheumatoid arthritis associated with oral contraceptives. Lancet I: 569Google Scholar
  188. Royal College of General Practitioners’ Oral Contraceptive Study (1981a) Further analysis of mortality in oral contraceptive users. Lancet I: 541Google Scholar
  189. Royal College of General Practitioners’ Oral Contraceptive Study (1981b) Breast cancer and oral contraceptives: findings in Royal College of General Practitioners’ study. Br Med J 282: 2089CrossRefGoogle Scholar
  190. Royal College of General Practitioners (1983) Incidence of arterial disease among oral contraceptive users. J R Coll Gen Pract 33:75Google Scholar
  191. Rubin GL, Ory HW, Layde PM (1982) Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 144: 630PubMedGoogle Scholar
  192. Runnebaum B, Rabe T (1987) New progestogens in oral contraceptives. Am J Obstet Gynecol 157:1059PubMedGoogle Scholar
  193. Rydén G, Fahraeus L, Molin L, Ahman K (1979) Do contraceptives influence the incidence of acute pelvic inflammatory diseases in women with gonorrhea? Contraception 20: 149PubMedCrossRefGoogle Scholar
  194. Samani F, Bolzonello P, Fior R, Elia A (1987) Effects on hearing during prolonged oral contraceptive use. Contraception 35:41PubMedCrossRefGoogle Scholar
  195. Savolainen E, Saksela E, Saxen L (1981) Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Am J Obstet Gynecol 140: 521PubMedGoogle Scholar
  196. Schindler AE (1984) Hormonale postkoitale Kontrazeption. Frauenarzt 2: 47Google Scholar
  197. Schindler AE (1989) ätiologie und Epidemiologie gutartiger Brustveränderungen der Brust. Gynäkologe 22: 212PubMedGoogle Scholar
  198. Schlesselman JJ, Stadel BV, Murray P, Wingo PA, Rubin GL (1987) Consistency and plausibility in epidemiologic analysis: application to breast cancer in relation to use of oral contraceptives. J Chron Dis 40:1033PubMedCrossRefGoogle Scholar
  199. Schley G, Anlauf M, Bock KD (1976) Orale Kontrazeptiva zur Prophylaxe akuter Schübe der intermittierenden Porphyrie. Dtsch Med Wochenschr 101:1901PubMedCrossRefGoogle Scholar
  200. Scholten PC, van Eykeren MA, Christiaens GCML, Haspels AA (1989) Menstrual blood loss with Levonorgestrel Nova-T and multiload CU 250 intrauterine devices. In: Scholten PC. The Levonorgestrel IUD — clinical performance and impact on menstruation. Habil Schrift Dept Obstet Gynaecol, University Hospital Uetrecht p. 35Google Scholar
  201. Schützel H, Neumann F (1988) Potential risk of intrauterine feminization in man from the antiandrogen cyproterone acetate (CPA) in recommended dose regiments. (XII World Congress of Gynecology and Obstetrics, Rio de Janeiro, Oct 23–28 1988, under auspices of International Federation of Gynecology & Obstetrics) Abstracts, p 703Google Scholar
  202. Schwartz U (1986) Kontrazeption in der Prämenopause. Gynäkologe 19: 254PubMedGoogle Scholar
  203. Scott LD, Katz AR, Duke JH, Cowan DF, Maklad NF (1984) Oral contraceptives, pregnancy, and focal nodular hyperplasia of the liver. JAMA 251:1461PubMedCrossRefGoogle Scholar
  204. Seed M, Godsland IF, Wynn V, Jacobs HS (1984) The effects of cyproterone acetate and ethinyl o estradiol on carbohydrate metabolism. Clin Endocrinol 21: 689CrossRefGoogle Scholar
  205. Shaffer EA, Taylor PJ, Logan K et al. (1984) The effect of a progestin on gallbladder function in young women. Am J Obstet Gynecol 148: 504PubMedGoogle Scholar
  206. Shaw RW (1987) Adverse longterm effects of oral contraceptives: a review. Br J Obstet Gynecol 94: 724CrossRefGoogle Scholar
  207. Sillem M, Teichmann AT (1994) The liver. In: Goldzieher J (ed) Pharmacology of the contraceptive steroids. Raven Press, New YorkGoogle Scholar
  208. Silverberg SG, Makowski EL (1975) Endometrial carcinoma in young women taking oral contraceptive agents. Obstet Gynecol 46:503PubMedGoogle Scholar
  209. Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T (1986) Endometrial morphology during long-term use of Levonorgestrel-releasing intrauterine devices. Int J Gynaecol Pathol 5: 235CrossRefGoogle Scholar
  210. Skouby SO (1988) Oral contraceptives: effects on glucose and lipid metabolism in insulin-dependent diabetic women and women with previous gestational diabetes. Danish Med Bull 35: 157PubMedGoogle Scholar
  211. Skouby SO, Jensen BM, Kühl C, Molsted-Pedersen L, Svenstrup B, Nielsen J (1985) Hormonal contraception in diabetic women: acceptability and influence on diabetes control and ovarian function of a non-alkylated estrogen/progestogen compound. Contraception 32: 23PubMedCrossRefGoogle Scholar
  212. Skouby SO, Molsted-Pedersen L, Kühl C, Bennet P (1986) Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles. Fertil Steril 46: 858PubMedGoogle Scholar
  213. Sooriyamoorthy M, Gower DB (1989) Hormonal influences on gingival tissue: relationship to periodontal disease. J Clin Periodontol 16: 201PubMedCrossRefGoogle Scholar
  214. Spellacy WN (1982) Carbohydrate metabolism during treatment with estrogen, progestogen, and low dose oral contraceptives. Am J Obstet Gynecol 142: 732PubMedGoogle Scholar
  215. Spellacy WN, Carlson KL, Birk SA (1967) Carbohydrate metabolic studies after six cycles of combined type oral contraceptive tablets. Diabetes 16: 590PubMedGoogle Scholar
  216. Spellacy WN, Carlson KL, Schade SL (1968) Effect of a sequential oral contraceptive on plasma insulin and blood glucose levels after 6 months’treatment. Am J Obstet Gynecol 101:672Google Scholar
  217. Stadel BV, Lai S, Schlesselman JJ, Murray P (1988) Oral contraceptives and premenopausal breast cancer in nulliparous women. Contraception 38: 287PubMedCrossRefGoogle Scholar
  218. Stamm H, Kraus J (1977) Pharmakotherapeutische Grundlagen der hormonellen Kontrazeption. Mod Arzneimittel Ther 1/4: 243Google Scholar
  219. Stampfer MJ, Wille« WC, Colditz GA et al. (1988) A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 319:1313PubMedCrossRefGoogle Scholar
  220. Stephan F, Réville P (1977) Diabetes und östrogene-Gestagene. MMW 119: 663Google Scholar
  221. Stern E, Forsythe AB, Yonkels L, Coeffelt CC (1977) Steroid contraceptive use and cervical dysplasia: increased risk in progression. Science 196:1460PubMedCrossRefGoogle Scholar
  222. Stone M, Bagshawe KD (1979) An analysis of the influence of maternal age, gestational age, contraceptive method, and the mode of primary treatment of patients with hydatidiform moles on the incidence of subsequent chemotherapy. Br J Obstet Gynecol 86: 782CrossRefGoogle Scholar
  223. Svensson L, Weström L, Mardh PA (1984) Contraceptives and acute salpingitis. JAMA 251: 2553PubMedCrossRefGoogle Scholar
  224. Sweet JB, Butler DP (1977) Increased incidence of postoperative localized osteitis in mandibular third molar surgery associated with patients using oral contraceptives. Am J Obstet Gynecol 127:518PubMedGoogle Scholar
  225. Tankeyoon M, Dusitsin N, Chalapati S (1984) Effects of hormonal contraceptives on milk volume and infant growth. Contraception 30:505PubMedCrossRefGoogle Scholar
  226. Taubert HD, Kuhl H (1995) Kontrazeption mit Hormonen. Thieme, Stuttgart, S 172Google Scholar
  227. Tayob Y, Adams J, Jacobs HS, Guillebaud J (1985) Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen only oral contraception. Br J Obstet Gynecol 92:1003CrossRefGoogle Scholar
  228. Teichmann AT (1996) Empfängnisverhütung. Thieme, StuttgartGoogle Scholar
  229. Teichmann AT, Wieland H, Brockerhoff P (1989) Sexualhormone, Arteriosklerose und Fettstoffwechsel der Frau. Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  230. Terblanche J (1978) Liver tumours associated with the use of contraceptive pills. S Afr MedJ 53: 439Google Scholar
  231. Tietze C, Lewit S (1978) Life risks associated with reversible methods of fertility regulation. (International symposium on a reappraisal of fertility control: benefits vs risks, Montreal)Google Scholar
  232. Tremblay RR, Dube JY (1974) Plasma concentration of free and non-TeBG bound testosterone in women on oral contraceptives. Contraception 10: 599PubMedCrossRefGoogle Scholar
  233. Ursin G, Peter RK, Henderson BE, Ablaing G III, Monroe KR, Pike MC (1994) Oral contraceptive use and adenocarcinoma of cervix. Lancet 344:1390PubMedCrossRefGoogle Scholar
  234. Vail JT (1967) Porphyria cutanea tarda and estrogens. JAMA 201:101CrossRefGoogle Scholar
  235. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR (1994) Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344:1453PubMedCrossRefGoogle Scholar
  236. Vesper B, Feustel S (1988) Die Beeinflussung der Serumlipide und der Glucosetoleranz durch Sequenz-Ovosiston und Minisiston. Zentralbl Gynäkol 110: 241PubMedGoogle Scholar
  237. Vessey MP, Doll R, Sutton PM (1972) Oral contraceptives and breast neoplasia: a retrospective study. Br Med J III: 719CrossRefGoogle Scholar
  238. Vessey MP, Doll R, Sutton PM (1975) Oral contraceptives and breast cancer: progress report of an epidemiological study. Lancet I: 941CrossRefGoogle Scholar
  239. Vessey MP, Doll R, Peto R, Johnson B, Wiggins P (1976) A long-term follow-up study of women using different methods of contraception — an interim report. J Biosoc Sci 8:375CrossRefGoogle Scholar
  240. Vessey MP, McPherson K, Johnson B (1977) Mortality among women participating in the Oxford/Family Planning Association Contraceptive Study. Lancet II: 731CrossRefGoogle Scholar
  241. Vessey MP, Wright NH, McPherson K, Yeates P (1978) Fertility after stopping different methods of contraception. Br Med J 1: 265PubMedCrossRefGoogle Scholar
  242. Vessey MP, Doll R, Jones K, McPherson K, Yeates P (1979) An epidemiological study of oral contraceptives and breast cancer. Br Med J 1:1757PubMedCrossRefGoogle Scholar
  243. Vessey MP, McPherson K, Yeates D, Doll R (1982) Oral contraceptive use and abortion before first term pregnancy in relation to breast cancer risk. Br J Cancer 45:327PubMedCrossRefGoogle Scholar
  244. Vessey MP, Metcalfe A, Wells C, McPherson K, Westhoff C, Yeates D (1987) Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. Br Med J 294:1518CrossRefGoogle Scholar
  245. Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D (1989) Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer 59: 613PubMedCrossRefGoogle Scholar
  246. Washington AE, Gove S, Schachter J et al. (1985) Oral contraceptives, chlamydia trachomatis infection, and pelvic inflammatory disease. JAMA 253: 2246PubMedCrossRefGoogle Scholar
  247. Weir RJ, Davies DL, Fraser R, Morton JJ, Tree M, Wilson A (1975) Contraceptive steroids and hypertension. J Steroid Biochem 6: 961PubMedCrossRefGoogle Scholar
  248. Weir JC, Silberman SL, Cohen LA (1979) Recurring oral pregnancy tumors. Obstet Gynecol 54: 358PubMedGoogle Scholar
  249. Weisberg E (1982) Fertility after discontinuation of oral contraceptives. Clin Reprod Fertil 1: 261PubMedGoogle Scholar
  250. Weiland FH, Hellman ES, Collins A, Hunter GW, Tschudy DP (1964) Factors affecting the excretion of porphyrin precursors by patients with acute intermittent porphyria. II. The effect of ethinyl estradiol. Metabolism 13: 251CrossRefGoogle Scholar
  251. Wenderlein JM (1981) Keine Häufung von Depressionen unter hormonaler Kontrazeption. Med Klin 76: 288PubMedGoogle Scholar
  252. WHO (1995a) Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346:1582Google Scholar
  253. WHO (1995b) Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case control study. Lancet 346:1575Google Scholar
  254. Wiebe RH, Morris CV (1984) Effect of an oral contraceptive on adrenal and ovarian androgenic steroids. Obstet Gynecol 63: 12PubMedGoogle Scholar
  255. Wingrave SJ, Kay CR, Vessey MP (1979) Oral contraceptives and diabetes mellitus. Br Med J 1: 23PubMedCrossRefGoogle Scholar
  256. Winkler UH, Schindler AE, Endrikat J, Düsterberg B (1996) A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 ug and 30 ug ethinylestradiol. Contraception 53: 75PubMedCrossRefGoogle Scholar
  257. Wiseman RA (1984) Absence of correlation between oral contraceptive usage and cardiovascular mortality. Int J Fertil 29: 198PubMedGoogle Scholar
  258. Wissenschaftlicher Beirat der Bundesärztekammer (1984) Hinweise zur Verordnung oraler Kontrazeptiva. Dtsch ärztebl 81: 1Google Scholar
  259. Woods JW (1988) Oral contraceptives and hypertension. Hypertension 11 (Suppl II): 11Google Scholar
  260. Woutersz TB (1983) A new ultra-low-dose combination oral contraceptive. J Reprod Med 28 (Suppl): 81PubMedGoogle Scholar
  261. Wu ML, Whittemore AS, Paffenbarger RS Jr et al. (1988) Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 128:1216PubMedGoogle Scholar
  262. Wynn V (1982a) Effect of duration of lowdose oral contraceptive administration on carbohydrate metabolism. Am J Obstet Gynecol 142: 739PubMedGoogle Scholar
  263. Wynn V (1982b) Cardiovascular effects of progestins in oral contraceptives. Am J Obstet Gynecol 142: 718PubMedGoogle Scholar
  264. Wynn V, Godsland I (1986) Effects of oral contraceptives on carbohydrate metabolism. J Reprod Med 31: 892PubMedGoogle Scholar
  265. Yuen BH, Burch P (1983) Relationship of oral contraceptives and the intrauterine contraceptive devices to the regression of concentration of the beta subunit of human chorionic gonadotropin and invasive complications after molar pregnancy. Am J Obstet Gynecol 145: 214Google Scholar
  266. Yuzpe AA, Smith RP, Rademaker AW (1982) A multicenter clinical investigation employing ethinyl estradiol combined with dl-norgestrel as a postcoital contraceptive agent. Fertil Steril 37: 508PubMedGoogle Scholar
  267. Zaun H (1980) Orale Kontrazeptiva und Hautveränderungen. Dtsch ärztebl 77:2347Google Scholar
  268. Zaun H (1982) Dermatotrope Wirkungen hormonaler Kontrazeptiva. In: Kaiser R (Hrsg) Hormonale Kontrazeption -aktuelle medizinische und juristische Aspekte. Schering, Berlin, S 15Google Scholar
  269. Zimmermann T (1996) persönliche Mitteilung, Daten aus Erhebung der PharmaindustrieGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Freimut A. Leidenberger
    • 1
    • 2
  1. 1.IHF Institut für Hormon- und FortpflanzungsforschungUniversität HamburgHamburgDeutschland
  2. 2.Endokrinologische Praxisgemeinschaft Leidenberger, Weise, Schulte, BreustedtHamburgDeutschland

Personalised recommendations